Department of Pulmonary and Critical Care Medicine, Peking University People's Hospital, Beijing, 100044, China.
Department of Clinical Laboratory, Peking University People's Hospital, Beijing, 100044, China.
BMC Infect Dis. 2021 Nov 24;21(1):1183. doi: 10.1186/s12879-021-06881-3.
We investigate the long-term effects of SARS-CoV on patients' lung and immune systems 15 years post-infection. SARS-CoV-2 pandemic is ongoing however, another genetically related beta-coronavirus SARS-CoV caused an epidemic in 2003-2004.
We enrolled 58 healthcare workers from Peking University People's Hospital who were infected with SARS-CoV in 2003. We evaluated lung damage by mMRC score, pulmonary function tests, and chest CT. Immune function was assessed by their serum levels of globin, complete components, and peripheral T cell subsets. ELISA was used to detect SARS-CoV-specific IgG antibodies in sera.
After 15 years of disease onset, 19 (36.5%), 8 (34.6%), and 19 (36.5%) subjects had impaired DL (CO), RV, and FEF, respectively. 17 (30.4%) subjects had an mMRC score ≥ 2. Fourteen (25.5%) cases had residual CT abnormalities. T regulatory cells were a bit higher in the SARS survivors. IgG antibodies against SARS S-RBD protein and N protein were detected in 11 (18.97%) and 12 (20.69%) subjects, respectively. Subgroup analysis revealed that small airway dysfunction and CT abnormalities were more common in the severe group than in the non-severe group (57.1% vs 22.6%, 54.5% vs 6.1%, respectively, p < 0.05).
SARS-CoV could cause permanent damage to the lung, which requires early pulmonary rehabilitation. The long-lived immune memory response against coronavirus requires further studies to assess the potential benefit. Trial registration ClinicalTrials.gov, NCT03443102. Registered prospectively on 25 January 2018.
我们调查了 SARS-CoV 在感染后 15 年对患者肺部和免疫系统的长期影响。然而,SARS-CoV-2 大流行仍在继续,另一种遗传上相关的β冠状病毒 SARS-CoV 在 2003-2004 年引发了一次疫情。
我们招募了 58 名来自北京大学人民医院的医护人员,他们在 2003 年感染了 SARS-CoV。我们通过 mMRC 评分、肺功能检查和胸部 CT 评估肺部损伤。通过血清球蛋白、全成分和外周 T 细胞亚群评估免疫功能。酶联免疫吸附试验用于检测血清中 SARS-CoV 特异性 IgG 抗体。
发病 15 年后,19 名(36.5%)、8 名(34.6%)和 19 名(36.5%)患者分别存在弥散功能(DL(CO))、残气量(RV)和用力呼气中期流速(FEF)受损。17 名(30.4%)患者 mMRC 评分≥2。14 例(25.5%)患者存在残留 CT 异常。SARS 幸存者的 T 调节细胞略高。11 名(18.97%)和 12 名(20.69%)患者分别检测到针对 SARS S-RBD 蛋白和 N 蛋白的 IgG 抗体。亚组分析显示,重症组小气道功能障碍和 CT 异常较非重症组更为常见(57.1%比 22.6%,54.5%比 6.1%,p<0.05)。
SARS-CoV 可导致肺部永久性损伤,需要早期肺康复。针对冠状病毒的持久免疫记忆反应需要进一步研究,以评估其潜在获益。
ClinicalTrials.gov,NCT03443102。于 2018 年 1 月 25 日进行前瞻性注册。